Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Alterity Therapeutics Ltd. ( (AU:ATH) ) has shared an update.
Alterity Therapeutics announced securing funds to expedite the clinical and business development of ATH434, their leading drug candidate for treating neurodegenerative diseases like MSA. The capital, raised through an ATM facility and augmented by Australian government rebates, will support Alterity’s advancement in clinical trials and regulatory activities, enhancing its industry positioning and offering potential benefits to stakeholders.
More about Alterity Therapeutics Ltd.
Alterity Therapeutics is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. Their lead asset, ATH434, targets Parkinsonian disorders, especially Multiple System Atrophy (MSA), with ongoing Phase 2 clinical trials. Alterity operates from Melbourne, Australia, and San Francisco, USA.
YTD Price Performance: 0%
Average Trading Volume: 100
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $39.87M
For a thorough assessment of ATH stock, go to TipRanks’ Stock Analysis page.
